Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomiz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in medicine 2021-07, Vol.8, p.668698-668698
Hauptverfasser: McCoy, John, Goren, Andy, Cadegiani, Flávio Adsuara, Vaño-Galván, Sergio, Kovacevic, Maja, Situm, Mirna, Shapiro, Jerry, Sinclair, Rodney, Tosti, Antonella, Stanimirovic, Andrija, Fonseca, Daniel, Dorner, Edinete, Onety, Dirce Costa, Zimerman, Ricardo Ariel, Wambier, Carlos Gustavo
Format: Artikel
Sprache:eng
Schlagworte:
Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomized, double-blinded, placebo-controlled clinical trial was conducted at two outpatient centers (Brasilia, Brazil). Patients were recruited from October 21 to December 24, 2020 (clinicaltrials.gov number, NCT04446429). Male patients with confirmed COVID-19 but not requiring hospitalization (COVID-19 8-point ordinal scale
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2021.668698